Content about Multiple sclerosis

April 4, 2013
Reports: Novartis launches new ad campaign aimed at young adults

Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

March 27, 2013
FDA approves new MS drug

The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said.

March 22, 2013
Genzyme drug shows improvement in MS patients

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

March 11, 2013
Early detection of PML in multiple sclerosis patients treated with immune-suppressing drugs may improve survival

Early detection of a deadly brain infection that sometimes arises due to treatment of autoimmune disorders with immune-suppressing biotech drugs may improve survival, according to a new study.

January 28, 2013
FDA accepts application for Genzyme MS drug

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

January 4, 2013
FDA approves new delivery method for MS drug

The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

November 1, 2012
Global MS market to reach $19.5 billion in 2017, report finds

The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.

September 13, 2012
FDA approves new MS drug

The Food and Drug Administration has approved a new drug for multiple sclerosis.

August 27, 2012
Genzyme provides update on Lemtrada filing with FDA

Genzyme announced it has received a refuse-to-file letter from the Food and Drug Administration in response to the drug maker's supplemental biologics license application for the approval of Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis.

August 8, 2012
Teva, Active Biotech plan third MS drug trial

Drug makers Teva Pharmaceutical Industries and Active Biotech will start a third late-stage clinical trial of an experimental drug for treating multiple sclerosis, the companies said Wednesday.

June 12, 2012
Genzyme seeks regulatory approval for Lemtrada

A Sanofi company is seeking regulatory approval from the Food and Drug Administration for a drug designed to treat relapsing multiple sclerosis.

June 1, 2012
Patients with MS show reduction in symptoms during drug trial

An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

April 20, 2012
Genzyme to present MS drug trials

Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

March 15, 2012
Late-stage trial of MS drug shows positive results

A drug under investigation by Teva Pharmaceutical Industries and Active Biotech reduced symptoms and progression of disease in patients with multiple sclerosis, according to results of a late-stage clinical trial.

March 8, 2012
Prime Therapeutics, Merck KGaA subsidiary enter contractual agreement over MS drug

A pharmacy benefit manager and the U.S. subsidiary of a German drug maker have made a deal concerning a drug for multiple sclerosis.

December 21, 2011
Genzyme reports lackluster results in MS drug trial

An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.

November 14, 2011
Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

October 12, 2011
Teva's Copaxone reduced brain volume loss in patients, according to study

Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.

October 6, 2011
Sanofi MS drug shows good results in phase-3 trial

A drug under investigation by Sanofi for multiple sclerosis improved several measures of disease activity in patients, according to results of a late-stage clinical trial.

August 2, 2011
FDA gives new approval to Novartis MS drug

The Food and Drug Administration has approved a new use for a drug made by Novartis for treating multiple sclerosis, the Swiss drug maker's U.S. subsidiary said Monday.

June 20, 2011
Mylan wins summary judgment pertaining to generic Copaxone

Mylan has scored a victory in its efforts to make a generic version of a Teva drug for multiple sclerosis.

May 25, 2011
Biogen Idec introduces Women in MS educational initiative

Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

April 28, 2011
Don Francisco's Coffee introduces limited-edition coffee to benefit MS campaign

Don Francisco's Coffee announced an exclusive and limited-edition coffee created for the Nancy Davis Foundation for Multiple Sclerosis.

April 20, 2011
Laura Geller supports MS awareness with Bring on the Bronze kit

Laura Geller, whose beauty products are sold at Ulta and Macy's Impulse locations, has partnered with Race to Erase MS and the Nancy Davis Foundation for Multiple Sclerosis to help raise awareness and funds for those afflicted with MS by creating a limited-edition Bring on the Bronze beauty kit.

April 12, 2011
Teva, Active Biotech: Laquinimod reduces relapses, disease progression in MS patients

An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

© 2013 Drug Store News. All Rights Reserved.